Helix Medical Opens Medical Device Manufacturing Operations in Europe

Helix Medical Opens Medical Device Manufacturing Operations in Europe

February 16, 2010

Carpinteria, CA -- Helix Medical, LLC, a global manufacturer for the medical device, health care, pharmaceutical, IVD, and biotech industries, announces the opening of Helix Medical Europe KG.

Helix Medical Europe begins production this month at their newly built, state-of-the-art, 55,000 square foot facility located in Kaiserslautern, Germany. Initial manufacturing services will include custom molding of silicone components for medical devices. Within the next 12 months they plan to add custom molding of thermoplastics and TPE's, multi-component molding, as well as close tolerance single and multi-lumen extrusion of silicone and TPE's.

"Our objective is to move our operations closer to our customers so that we can serve their manufacturing and distribution needs on a global level," said Dr. Jorg Schneewind, President & CEO of Helix Medical, LLC. "The fact that we were able to build on the infrastructure of an existing facility owned by our parent company, Freudenberg, created a tremendous opportunity or European expansion."

For more information on Helix Medical Europe KG please contact Thomas M. Vassallo, EVP Global Business Development at (805)684-3304.

About Helix Medical

Helix Medical, LLC is a subsidiary of Freudenberg-NOK General Partnership and its operations comprise the Health Care Products division of Freudenberg-NOK. Founded in 1984, Helix Medical is a global custom manufacturer for the medical device, health care, pharmaceutical, IVD and biotech industries. Manufacturing capabilities include silicone molding (LSR, HCR), thermoplastic molding, close tolerance multi-lumen extrusion, assembly, and packaging. Headquartered in Carpinteria, CA, Helix Medical operates an FDA-registered medical device facility, certified ISO 13485 with ISO 14644 Class 7 & 8 cleanrooms. Additional medical manufacturing operations are located in Baldwin Park, CA; Gloucester, MA; Shenzhen, China; and Kaiserslautern, Germany. www.helixmedical.com

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.